Drug Development, Protocols

Protocols: RaNA recruits Shire vet as new CSO; Catalent buys Pharmatek

The Cambridge, MA-based RNA expert RaNA Therapeutics has recruited Thomas McCauley, a Shire vet, as its new CSO.

Somerset, NJ-based Catalent has bought up Pharmatek Laboratories, a drug development and clinical manufacturing operation. The acquisition will add some additional tech for formulation and delivery, with a network that specializes in early-stage work. Pharmatek has a cGMP facility in San Diego that employs nearly 200 people.

Evanston, IL-based Aptinyx nabbed fast track status for its lead compound, NYX-2925, as a treatment for neuropathic pain associated with diabetic peripheral neuropathy.

San Diego-based AmpliPhi Biosciences has put out top line data from a Phase I safety study of AB-SA01, a cocktail targeting Staphylococcus aureus (S. aureus) infections. Investigators say the cocktail was well tolerated.

 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 32,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Director, Financial Planning and Analysis
Molecular Templates Austin, TX
Manufacturing Associate – Downstream
Molecular Templates Austin, TX
Senior Statistician
Koneksa Health New York, NY

Visit Endpoints Careers ->